person · Reporting owner

Kariv Tomer

Disclosed activity across 6 companies

Tapewire entity: 74168
SEC CIK: 0001568077

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
89bio, Inc.ETNB · Entity 73682	Director · 10% owner	November 11, 2019	November 14, 2019
Arno Therapeutics, IncARNI · Entity 179806	Director · 10% owner	January 25, 2013	September 08, 2016
Eloxx Pharmaceuticals, Inc.ELOX · Entity 7180	Director	January 30, 2023	January 31, 2023
LogicBio Therapeutics, Inc.LOGC · Entity 122292	Director	December 19, 2019	December 20, 2019
VBI Vaccines Inc/BCVBIV · Entity 111039	Director	January 31, 2019	February 04, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

89bio, Inc.

Report date November 11, 2019 · Filed November 14, 2019

Jointly reported with Pontifax (Israel) V, L.P., Pontifax (Cayman) V, L.P., Pontifax (China) V, L.P., Pontifax 5 G.P. L.P., Pontifax Management 4 G.P. (2015) Ltd., Pontifax Late Stage GP Ltd., Pontifax Late Stage Fund L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnotes	250,000	Reported balance After 2019-11-11 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2019-11-11 · Purchase · Acquired 250,000 · Balance 250,000 F1: On November 11, 2019, Pontifax (Israel) V, L.P. purchased 134,390 shares of the Issuer's common stock, Pontifax (Cayman) V, L.P. purchased 35,897 shares of the Issuer's common stock, Pontifax (China) V, L.P. (collectively, the "Pontifax Entities") purchased 52,213 shares of the Issuer's common stock and Pontifax Late Stage Fund L.P. ("Late Stage L.P.") purchased 27,500 shares of the Issuer's common stock at a price of $16.00 per share in the Issuer's initial public offering. F3: Includes (a) 134,390 shares held by Pontifax (Israel) V, L.P., (b) 35,897 shares held by Pontifax (Cayman) V, L.P., (c) 52,213 shares held by Pontifax (China) V, L.P. and (d) 27,500 shares held by Late Stage L.P. F6: Pontifax 5 G.P. L.P. ("Pontifax 5 GP") is the general partner of each of the Pontifax Entities, and Pontifax Management 4 G.P. (2015) Ltd. ("Pontifax Management") is the general partner of Pontifax 5 GP. Mr. Tomer Kariv is one of two Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. Mr. Kariv disclaims beneficial ownership of those shares held by the Pontifax Entities, except to the extent of his pecuniary interest therein. Late Stage L.P. invests side by side with Pontifax 5 GP pursuant to a Strategic Alliance Agreement with Pontifax 5 GP. Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage L.P. F7: (Continued from footnote 6) and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. By virtue of the strategic relationship, each of Pontifax 5 GP, Pontifax Management, Ran Nussbaum, and Tomer Kariv may be deemed to share voting and dispositive power with respect to the shares held by Late Stage L.P. in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax Entities. In that context, Mr. Kariv disclaims beneficial ownership of such shares, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.
Common StockSEC Table I · non-derivative	IndirectSee footnotes	1,134,671	Reported balance After 2019-11-13 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2019-11-13 · Conversion · Acquired 884,671 · Balance 1,134,671 F2: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date. F4: Includes (a) 668,732 shares held by Pontifax (Israel) V, L.P., (b) 178,623 shares held by Pontifax (Cayman) V, L.P., (c) 259,816 shares held by Pontifax (China) V, L.P. and (d) 27,500 shares held by Late Stage L.P. F6: Pontifax 5 G.P. L.P. ("Pontifax 5 GP") is the general partner of each of the Pontifax Entities, and Pontifax Management 4 G.P. (2015) Ltd. ("Pontifax Management") is the general partner of Pontifax 5 GP. Mr. Tomer Kariv is one of two Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. Mr. Kariv disclaims beneficial ownership of those shares held by the Pontifax Entities, except to the extent of his pecuniary interest therein. Late Stage L.P. invests side by side with Pontifax 5 GP pursuant to a Strategic Alliance Agreement with Pontifax 5 GP. Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage L.P. F7: (Continued from footnote 6) and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. By virtue of the strategic relationship, each of Pontifax 5 GP, Pontifax Management, Ran Nussbaum, and Tomer Kariv may be deemed to share voting and dispositive power with respect to the shares held by Late Stage L.P. in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax Entities. In that context, Mr. Kariv disclaims beneficial ownership of such shares, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnotes	0	Reported balance After 2019-11-13 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-11-13 · Conversion · Disposed 5,500,001 · Balance 0 F2: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date. F5: Includes (a) 534,342 shares held by Pontifax (Israel) V, L.P., (b) 142,726 shares held by Pontifax (Cayman) V, L.P. and (c) 207,603 shares held by Pontifax (China) V, L.P. F6: Pontifax 5 G.P. L.P. ("Pontifax 5 GP") is the general partner of each of the Pontifax Entities, and Pontifax Management 4 G.P. (2015) Ltd. ("Pontifax Management") is the general partner of Pontifax 5 GP. Mr. Tomer Kariv is one of two Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. Mr. Kariv disclaims beneficial ownership of those shares held by the Pontifax Entities, except to the extent of his pecuniary interest therein. Late Stage L.P. invests side by side with Pontifax 5 GP pursuant to a Strategic Alliance Agreement with Pontifax 5 GP. Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage L.P. F7: (Continued from footnote 6) and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. By virtue of the strategic relationship, each of Pontifax 5 GP, Pontifax Management, Ran Nussbaum, and Tomer Kariv may be deemed to share voting and dispositive power with respect to the shares held by Late Stage L.P. in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax Entities. In that context, Mr. Kariv disclaims beneficial ownership of such shares, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.

Filing footnotes · ownership attribution and instrument terms

F1: On November 11, 2019, Pontifax (Israel) V, L.P. purchased 134,390 shares of the Issuer's common stock, Pontifax (Cayman) V, L.P. purchased 35,897 shares of the Issuer's common stock, Pontifax (China) V, L.P. (collectively, the "Pontifax Entities") purchased 52,213 shares of the Issuer's common stock and Pontifax Late Stage Fund L.P. ("Late Stage L.P.") purchased 27,500 shares of the Issuer's common stock at a price of $16.00 per share in the Issuer's initial public offering.

F2: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date.

F3: Includes (a) 134,390 shares held by Pontifax (Israel) V, L.P., (b) 35,897 shares held by Pontifax (Cayman) V, L.P., (c) 52,213 shares held by Pontifax (China) V, L.P. and (d) 27,500 shares held by Late Stage L.P.

F4: Includes (a) 668,732 shares held by Pontifax (Israel) V, L.P., (b) 178,623 shares held by Pontifax (Cayman) V, L.P., (c) 259,816 shares held by Pontifax (China) V, L.P. and (d) 27,500 shares held by Late Stage L.P.

F5: Includes (a) 534,342 shares held by Pontifax (Israel) V, L.P., (b) 142,726 shares held by Pontifax (Cayman) V, L.P. and (c) 207,603 shares held by Pontifax (China) V, L.P.

F6: Pontifax 5 G.P. L.P. ("Pontifax 5 GP") is the general partner of each of the Pontifax Entities, and Pontifax Management 4 G.P. (2015) Ltd. ("Pontifax Management") is the general partner of Pontifax 5 GP. Mr. Tomer Kariv is one of two Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. Mr. Kariv disclaims beneficial ownership of those shares held by the Pontifax Entities, except to the extent of his pecuniary interest therein. Late Stage L.P. invests side by side with Pontifax 5 GP pursuant to a Strategic Alliance Agreement with Pontifax 5 GP. Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage L.P.

F7: (Continued from footnote 6) and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. By virtue of the strategic relationship, each of Pontifax 5 GP, Pontifax Management, Ran Nussbaum, and Tomer Kariv may be deemed to share voting and dispositive power with respect to the shares held by Late Stage L.P. in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax Entities. In that context, Mr. Kariv disclaims beneficial ownership of such shares, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.

Arno Therapeutics, Inc

Report date January 25, 2013 · Filed September 08, 2016 · Amendment

Jointly reported with Pontifax Management II, L.P., Pontifax Management 2 G.P. (2007) Ltd., Nussbaum Ran

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Pontifax (Cayman) II L.P.	187,156	Reported balance Holding disclosure · report date 2013-01-25 · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · Balance 187,156 F1: This amendment is being filed to include Pontifax Management II, L.P. ("PM"), Pontifax Management 2 G.P. (2007) Ltd. ("PMGP") and Ran Nussbaum ("Nussbaum") as additional reporting persons to the Form 3 filed by Tomer Kariv ("Kariv") on 1/29/13 and to reflect Kariv as a 10% owner. The reporting persons have re-reported the securities held in Table I solely to gain access to the EDGAR filing system and the Amount of Securities Beneficially Owned has been adjusted to reflect a 1-for-8 combination of the Issuer's common stock completed on 10/29/13. F2: PM is the general partner of each of Pontifax (Cayman) II L.P. ("PC"), Pontifax (Israel) II L.P. ("PI") and Pontifax (Israel) II - Individual Investors L.P. ("PIII" and together with PC and PI, the "Pontifax Funds"). PMGP is the general partner of PM. Each of Kariv and Nussbaum are directors of PMGP. PM and PMGP, through the Pontifax Funds, share a contractual right to designate one member of the Issuer's board of directors and may be deemed to be directors by deputization for purposes of Section 16 of the Exchange Act. The purpose of this amendment is to add PM, PMGP and Nussbaum as reporting persons to the Form 3 originally filed by Kariv on 1/29/13 in order to reflect that the securities shown on such form as held by the Pontifax Funds are beneficially owned by PM, PMGP, Nussbaum and Kariv. F3: This form is also intended to amend the Form 4 statements filed by Kariv on each of 4/10/13, 5/7/13, 6/5/13, 10/31/13, 1/14/16 and 8/17/16, and a Form 5 filed on 2/17/15 (the "Prior Statements") to reflect that the securities shown therein as indirectly held by Kariv through the Pontifax Funds are also beneficially owned by PMII, PMGP and Nussbaum. Each of the reporting persons disclaims beneficial ownership of the securities held by the Pontifax Funds except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission by any reporting person that such person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act or for any other purpose. F4: Each of PM, PMGP and Nussbaum disclaims beneficial ownership of the securities directly held by Kariv as reflected in the Prior Statements, except to the extent of his or its pecuniary interest therein, and this Form 3/A shall not be deemed an admission by PM, PMGP or Nussbaum that any is a beneficial owner of any securities held by Kariv for purposes of Section 16 or any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy Pontifax (Israel) II L.P.	140,977	Reported balance Holding disclosure · report date 2013-01-25 · row 2 Amendment: may correct only part of an earlier disclosure. 1 source row Row 2 · Balance 140,977 F1: This amendment is being filed to include Pontifax Management II, L.P. ("PM"), Pontifax Management 2 G.P. (2007) Ltd. ("PMGP") and Ran Nussbaum ("Nussbaum") as additional reporting persons to the Form 3 filed by Tomer Kariv ("Kariv") on 1/29/13 and to reflect Kariv as a 10% owner. The reporting persons have re-reported the securities held in Table I solely to gain access to the EDGAR filing system and the Amount of Securities Beneficially Owned has been adjusted to reflect a 1-for-8 combination of the Issuer's common stock completed on 10/29/13. F2: PM is the general partner of each of Pontifax (Cayman) II L.P. ("PC"), Pontifax (Israel) II L.P. ("PI") and Pontifax (Israel) II - Individual Investors L.P. ("PIII" and together with PC and PI, the "Pontifax Funds"). PMGP is the general partner of PM. Each of Kariv and Nussbaum are directors of PMGP. PM and PMGP, through the Pontifax Funds, share a contractual right to designate one member of the Issuer's board of directors and may be deemed to be directors by deputization for purposes of Section 16 of the Exchange Act. The purpose of this amendment is to add PM, PMGP and Nussbaum as reporting persons to the Form 3 originally filed by Kariv on 1/29/13 in order to reflect that the securities shown on such form as held by the Pontifax Funds are beneficially owned by PM, PMGP, Nussbaum and Kariv. F3: This form is also intended to amend the Form 4 statements filed by Kariv on each of 4/10/13, 5/7/13, 6/5/13, 10/31/13, 1/14/16 and 8/17/16, and a Form 5 filed on 2/17/15 (the "Prior Statements") to reflect that the securities shown therein as indirectly held by Kariv through the Pontifax Funds are also beneficially owned by PMII, PMGP and Nussbaum. Each of the reporting persons disclaims beneficial ownership of the securities held by the Pontifax Funds except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission by any reporting person that such person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act or for any other purpose. F4: Each of PM, PMGP and Nussbaum disclaims beneficial ownership of the securities directly held by Kariv as reflected in the Prior Statements, except to the extent of his or its pecuniary interest therein, and this Form 3/A shall not be deemed an admission by PM, PMGP or Nussbaum that any is a beneficial owner of any securities held by Kariv for purposes of Section 16 or any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy Pontifax (Israel) II - Individual Investors L.P.	54,725	Reported balance Holding disclosure · report date 2013-01-25 · row 3 Amendment: may correct only part of an earlier disclosure. 1 source row Row 3 · Balance 54,725 F1: This amendment is being filed to include Pontifax Management II, L.P. ("PM"), Pontifax Management 2 G.P. (2007) Ltd. ("PMGP") and Ran Nussbaum ("Nussbaum") as additional reporting persons to the Form 3 filed by Tomer Kariv ("Kariv") on 1/29/13 and to reflect Kariv as a 10% owner. The reporting persons have re-reported the securities held in Table I solely to gain access to the EDGAR filing system and the Amount of Securities Beneficially Owned has been adjusted to reflect a 1-for-8 combination of the Issuer's common stock completed on 10/29/13. F2: PM is the general partner of each of Pontifax (Cayman) II L.P. ("PC"), Pontifax (Israel) II L.P. ("PI") and Pontifax (Israel) II - Individual Investors L.P. ("PIII" and together with PC and PI, the "Pontifax Funds"). PMGP is the general partner of PM. Each of Kariv and Nussbaum are directors of PMGP. PM and PMGP, through the Pontifax Funds, share a contractual right to designate one member of the Issuer's board of directors and may be deemed to be directors by deputization for purposes of Section 16 of the Exchange Act. The purpose of this amendment is to add PM, PMGP and Nussbaum as reporting persons to the Form 3 originally filed by Kariv on 1/29/13 in order to reflect that the securities shown on such form as held by the Pontifax Funds are beneficially owned by PM, PMGP, Nussbaum and Kariv. F3: This form is also intended to amend the Form 4 statements filed by Kariv on each of 4/10/13, 5/7/13, 6/5/13, 10/31/13, 1/14/16 and 8/17/16, and a Form 5 filed on 2/17/15 (the "Prior Statements") to reflect that the securities shown therein as indirectly held by Kariv through the Pontifax Funds are also beneficially owned by PMII, PMGP and Nussbaum. Each of the reporting persons disclaims beneficial ownership of the securities held by the Pontifax Funds except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission by any reporting person that such person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act or for any other purpose. F4: Each of PM, PMGP and Nussbaum disclaims beneficial ownership of the securities directly held by Kariv as reflected in the Prior Statements, except to the extent of his or its pecuniary interest therein, and this Form 3/A shall not be deemed an admission by PM, PMGP or Nussbaum that any is a beneficial owner of any securities held by Kariv for purposes of Section 16 or any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: This amendment is being filed to include Pontifax Management II, L.P. ("PM"), Pontifax Management 2 G.P. (2007) Ltd. ("PMGP") and Ran Nussbaum ("Nussbaum") as additional reporting persons to the Form 3 filed by Tomer Kariv ("Kariv") on 1/29/13 and to reflect Kariv as a 10% owner. The reporting persons have re-reported the securities held in Table I solely to gain access to the EDGAR filing system and the Amount of Securities Beneficially Owned has been adjusted to reflect a 1-for-8 combination of the Issuer's common stock completed on 10/29/13.

F2: PM is the general partner of each of Pontifax (Cayman) II L.P. ("PC"), Pontifax (Israel) II L.P. ("PI") and Pontifax (Israel) II - Individual Investors L.P. ("PIII" and together with PC and PI, the "Pontifax Funds"). PMGP is the general partner of PM. Each of Kariv and Nussbaum are directors of PMGP. PM and PMGP, through the Pontifax Funds, share a contractual right to designate one member of the Issuer's board of directors and may be deemed to be directors by deputization for purposes of Section 16 of the Exchange Act. The purpose of this amendment is to add PM, PMGP and Nussbaum as reporting persons to the Form 3 originally filed by Kariv on 1/29/13 in order to reflect that the securities shown on such form as held by the Pontifax Funds are beneficially owned by PM, PMGP, Nussbaum and Kariv.

F3: This form is also intended to amend the Form 4 statements filed by Kariv on each of 4/10/13, 5/7/13, 6/5/13, 10/31/13, 1/14/16 and 8/17/16, and a Form 5 filed on 2/17/15 (the "Prior Statements") to reflect that the securities shown therein as indirectly held by Kariv through the Pontifax Funds are also beneficially owned by PMII, PMGP and Nussbaum. Each of the reporting persons disclaims beneficial ownership of the securities held by the Pontifax Funds except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission by any reporting person that such person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act or for any other purpose.

F4: Each of PM, PMGP and Nussbaum disclaims beneficial ownership of the securities directly held by Kariv as reflected in the Prior Statements, except to the extent of his or its pecuniary interest therein, and this Form 3/A shall not be deemed an admission by PM, PMGP or Nussbaum that any is a beneficial owner of any securities held by Kariv for purposes of Section 16 or any other purpose.

Eloxx Pharmaceuticals, Inc.

Report date January 30, 2023 · Filed January 31, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2033-01-30	Direct	2,859	Reported balance After 2023-01-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-01-30 · Grant · Acquired 2,859 · Balance 2,859 F1: The stock option vests as to 50% of the underlying shares on the first anniversary of January 30, 2023, and the remaining 50% of the underlying shares will vest in twelve (12) equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. F2: The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests as to 50% of the underlying shares on the first anniversary of January 30, 2023, and the remaining 50% of the underlying shares will vest in twelve (12) equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

F2: The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner.

LogicBio Therapeutics, Inc.

Report date December 19, 2019 · Filed December 20, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.65 · Expires 2029-12-19	Direct	10,869	Reported balance After 2019-12-19 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-12-19 · Grant · Acquired 10,869 · Balance 10,869 F1: 100% vests on the earlier of 7/15/2020 or the 2020 Annual Meeting of Stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: 100% vests on the earlier of 7/15/2020 or the 2020 Annual Meeting of Stockholders.

VBI Vaccines Inc/BC

Report date January 31, 2019 · Filed February 04, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Option (Right to Buy Common Shares)SEC Table II · derivative / convertible security · Conversion / exercise price $1.64 · Expires 2029-01-31	Direct	200,000	Reported balance After 2019-01-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-01-31 · Grant · Acquired 200,000 · Balance 200,000 F1: Exercise price represents the volume weighted average closing price of the Issuer's common shares on the Nasdaq Capital Market for Grant Date (as defined below) and the four (4) trading days preceding the Grant Date. F2: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 31, 2019 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 31, 2019 (the "Option Agreement"). The options vest and become exercisable in 36 equal monthly installments beginning on the first day of the month following the Grant Date, subject to the reporting person's employment on the relevant vesting date. F3: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Exercise price represents the volume weighted average closing price of the Issuer's common shares on the Nasdaq Capital Market for Grant Date (as defined below) and the four (4) trading days preceding the Grant Date.

F2: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 31, 2019 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 31, 2019 (the "Option Agreement"). The options vest and become exercisable in 36 equal monthly installments beginning on the first day of the month following the Grant Date, subject to the reporting person's employment on the relevant vesting date.

F3: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Keros Therapeutics, Inc.

Report date October 15, 2025 · Filed October 17, 2025

Jointly reported with Pontifax Management 4 G.P. (2015) Ltd., Pontifax (Israel) IV, L.P., Pontifax (Cayman) IV L.P., Pontifax (China) IV L.P., Pontifax Late Stage Fund L.P., Pontifax Late Stage GP Ltd., Nussbaum Ran

Section 16 reporting ended · disclosed 2025-10-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.0001 par value per shareSEC Table I · non-derivative	IndirectBy Pontifax (Israel) IV, L.P.	0	Reported balance After 2025-10-15 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-10-15 · Sale · Disposed 2,284,612 · Balance 0 F1: The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by Israel IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.
Common Stock, $0.0001 par value per shareSEC Table I · non-derivative	IndirectBy Pontifax (Cayman) IV, L.P.	0	Reported balance After 2025-10-15 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2025-10-15 · Sale · Disposed 1,121,045 · Balance 0 F2: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.
Common Stock, $0.0001 par value per shareSEC Table I · non-derivative	IndirectBy Pontifax (China) IV, L.P.	0	Reported balance After 2025-10-15 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2025-10-15 · Sale · Disposed 1,226,412 · Balance 0 F3: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by China IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.
Common Stock, $0.0001 par value per shareSEC Table I · non-derivative	IndirectBy Pontifax Late Stage Fund, L.P.	0	Reported balance After 2025-10-15 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2025-10-15 · Sale · Disposed 155,262 · Balance 0 F4: The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to the Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, Management 4 and Tomer Kariv and Ran Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of his or its pecuniary interest therein.
Common Stock, $0.0001 par value per shareSEC Table I · non-derivative	IndirectBy Tomer Kariv	5,250	Reported balance Holding disclosure · report date 2025-10-15 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 5,250 F5: In connection with the Stock Purchase Agreement, dated October 15, 2025, by and among certain of the Reporting Persons and the Issuer and the resignations of each of Tomer Kariv and Ran Nussbaum from the Issuer's board of directors, the Issuer accelerated the vesting of the restricted stock unit awards and certain options held by Messrs. Kariv and Nussbaum that were previously reported in their respective Form 4 filings.
Common Stock, $0.0001 par value per shareSEC Table I · non-derivative	IndirectBy Ran Nussbaum	5,250	Reported balance Holding disclosure · report date 2025-10-15 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 5,250 F5: In connection with the Stock Purchase Agreement, dated October 15, 2025, by and among certain of the Reporting Persons and the Issuer and the resignations of each of Tomer Kariv and Ran Nussbaum from the Issuer's board of directors, the Issuer accelerated the vesting of the restricted stock unit awards and certain options held by Messrs. Kariv and Nussbaum that were previously reported in their respective Form 4 filings.

Filing footnotes · ownership attribution and instrument terms

F1: The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by Israel IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.

F2: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.

F3: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by China IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.

F4: The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to the Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, Management 4 and Tomer Kariv and Ran Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of his or its pecuniary interest therein.

F5: In connection with the Stock Purchase Agreement, dated October 15, 2025, by and among certain of the Reporting Persons and the Issuer and the resignations of each of Tomer Kariv and Ran Nussbaum from the Issuer's board of directors, the Issuer accelerated the vesting of the restricted stock unit awards and certain options held by Messrs. Kariv and Nussbaum that were previously reported in their respective Form 4 filings.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 15, 2025 Filed Oct 17, 2025 21:53 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	SaleCommon Stock, $0.0001 par value per share	155,262	$17.75	$2,755,900.50	Disclosure SEC source: 0000921895-25-002765 · form414601002_10172025.xml · nonDerivative · entry 4 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Kariv Tomer · CIK 0001568077 · Director · 10% owner Nussbaum Ran · CIK 0001609805 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Pontifax Late Stage Fund, L.P. Disclosed balance after: 0 F4 · ownership.nature: The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to the Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, Management 4 and Tomer Kariv and Ran Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of his or its pecuniary interest therein. Read SEC document
October 15, 2025 Filed Oct 17, 2025 21:53 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	SaleCommon Stock, $0.0001 par value per share	1,226,412	$17.75	$21,768,813.00	Disclosure SEC source: 0000921895-25-002765 · form414601002_10172025.xml · nonDerivative · entry 3 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Kariv Tomer · CIK 0001568077 · Director · 10% owner Nussbaum Ran · CIK 0001609805 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Pontifax (China) IV, L.P. Disclosed balance after: 0 F3 · ownership.nature: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by China IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Read SEC document
October 15, 2025 Filed Oct 17, 2025 21:53 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	SaleCommon Stock, $0.0001 par value per share	1,121,045	$17.75	$19,898,548.75	Disclosure SEC source: 0000921895-25-002765 · form414601002_10172025.xml · nonDerivative · entry 2 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Kariv Tomer · CIK 0001568077 · Director · 10% owner Nussbaum Ran · CIK 0001609805 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Pontifax (Cayman) IV, L.P. Disclosed balance after: 0 F2 · ownership.nature: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Read SEC document
October 15, 2025 Filed Oct 17, 2025 21:53 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	SaleCommon Stock, $0.0001 par value per share	2,284,612	$17.75	$40,551,863.00	Disclosure SEC source: 0000921895-25-002765 · form414601002_10172025.xml · nonDerivative · entry 1 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Kariv Tomer · CIK 0001568077 · Director · 10% owner Nussbaum Ran · CIK 0001609805 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Pontifax (Israel) IV, L.P. Disclosed balance after: 0 F1 · ownership.nature: The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by Israel IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Read SEC document
June 04, 2025 Filed Jun 6, 2025 16:15 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	GrantStock Option (right to buy) · Derivative	10,500	$0.00 Strike: $14.82	$0.00	Disclosure SEC source: 0001415889-25-015977 · form4-06062025_040613.xml · derivative · entry 5 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2035-06-03 F5 · derivative.exercise_date: The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document
June 04, 2025 Filed Jun 6, 2025 16:15 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	GrantCommon Stock	5,250	$0.00	$0.00	Disclosure SEC source: 0001415889-25-015977 · form4-06062025_040613.xml · nonDerivative · entry 1 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,250 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 4, 2026 and (B) the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document
May 30, 2024 Filed Jun 3, 2024 16:15 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $46.31	$0.00	Disclosure SEC source: 0001415889-24-015155 · form4-06032024_040615.xml · derivative · entry 1 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-05-29 F1 · derivative.exercise_date: The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document
June 06, 2023 Filed Jun 8, 2023 16:45 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $48.79	$0.00	Disclosure SEC source: 0001209191-23-035459 · doc4.xml · derivative · entry 1 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-06-05 F1 · derivative.exercise_date: The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document
January 30, 2023 Filed Jan 31, 2023 21:08 UTC	Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180	GrantStock Options (Right to Buy) · Derivative	2,859	$0.00 Strike: $4.00	$0.00	Disclosure SEC source: 0001104659-23-008599 · tm234943-2_4seq1.xml · derivative · entry 1 Kariv Tomer · CIK 0001568077 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,859 Underlying: Common Stock · 2,859 shares Expires 2033-01-30 F1 · derivative.exercise_date: The stock option vests as to 50% of the underlying shares on the first anniversary of January 30, 2023, and the remaining 50% of the underlying shares will vest in twelve (12) equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. F2 · ownership.direct: The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner. Read SEC document
November 29, 2022 Filed Nov 30, 2022 16:38 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	OtherCall Options (obligation to sell) · Derivative	1,914	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-22-059051 · doc4.xml · derivative · entry 6 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,914 shares Expires 2023-10-07 F1 · kind: Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. ("Israel IV"), Pontifax (Cayman) IV, L.P. ("Cayman IV") and Pontifax (China) IV, L.P. ("China IV") and a certain securityholder. F5 · derivative.exercise_date: Fully vested and exercisable. F4 · ownership.nature: The securities are held by China IV. Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
November 29, 2022 Filed Nov 30, 2022 16:38 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	OtherCall Options (obligation to sell) · Derivative	1,723	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-22-059051 · doc4.xml · derivative · entry 5 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,723 shares Expires 2023-10-07 F1 · kind: Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. ("Israel IV"), Pontifax (Cayman) IV, L.P. ("Cayman IV") and Pontifax (China) IV, L.P. ("China IV") and a certain securityholder. F5 · derivative.exercise_date: Fully vested and exercisable. F3 · ownership.nature: The securities are held by Cayman IV. Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
November 29, 2022 Filed Nov 30, 2022 16:38 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	OtherCall Options (obligation to sell) · Derivative	3,539	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-22-059051 · doc4.xml · derivative · entry 4 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 3,539 shares Expires 2023-10-07 F1 · kind: Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. ("Israel IV"), Pontifax (Cayman) IV, L.P. ("Cayman IV") and Pontifax (China) IV, L.P. ("China IV") and a certain securityholder. F5 · derivative.exercise_date: Fully vested and exercisable. F2 · ownership.nature: The securities are held by Israel IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
November 29, 2022 Filed Nov 30, 2022 16:38 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	OtherCommon Stock	1,914	$0.00	$0.19	Disclosure SEC source: 0001209191-22-059051 · doc4.xml · nonDerivative · entry 3 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,226,412 F1 · kind: Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. ("Israel IV"), Pontifax (Cayman) IV, L.P. ("Cayman IV") and Pontifax (China) IV, L.P. ("China IV") and a certain securityholder. F4 · ownership.nature: The securities are held by China IV. Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
November 29, 2022 Filed Nov 30, 2022 16:38 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	OtherCommon Stock	1,723	$0.00	$0.17	Disclosure SEC source: 0001209191-22-059051 · doc4.xml · nonDerivative · entry 2 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,121,045 F1 · kind: Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. ("Israel IV"), Pontifax (Cayman) IV, L.P. ("Cayman IV") and Pontifax (China) IV, L.P. ("China IV") and a certain securityholder. F3 · ownership.nature: The securities are held by Cayman IV. Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
November 29, 2022 Filed Nov 30, 2022 16:38 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	OtherCommon Stock	3,539	$0.00	$0.35	Disclosure SEC source: 0001209191-22-059051 · doc4.xml · nonDerivative · entry 1 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,284,612 F1 · kind: Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. ("Israel IV"), Pontifax (Cayman) IV, L.P. ("Cayman IV") and Pontifax (China) IV, L.P. ("China IV") and a certain securityholder. F2 · ownership.nature: The securities are held by Israel IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
June 15, 2022 Filed Jun 17, 2022 12:24 UTC	Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180	GrantStock Options (Right to Buy) · Derivative	20,000	$0.00 Strike: $0.26	$0.00	Disclosure SEC source: 0001104659-22-072176 · tm2218714-2_4seq1.xml · derivative · entry 1 Kariv Tomer · CIK 0001568077 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter. F2 · ownership.direct: The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner. Read SEC document
June 01, 2022 Filed Jun 3, 2022 16:27 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	GrantStock Options (right to buy) · Derivative	8,293	$0.00 Strike: $32.95	$0.00	Disclosure SEC source: 0001209191-22-034045 · doc4.xml · derivative · entry 1 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,293 Underlying: Common Stock · 8,293 shares Expires 2032-05-31 F1 · derivative.exercise_date: The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document
June 01, 2021 Filed Jun 3, 2021 17:31 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	GrantStock Option (right to buy) · Derivative	8,293	$0.00 Strike: $51.48	$0.00	Disclosure SEC source: 0001209191-21-037795 · doc4.xml · derivative · entry 1 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,293 Underlying: Common Stock · 8,293 shares Expires 2031-05-31 F1 · derivative.exercise_date: The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document
May 19, 2021 Filed May 20, 2021 20:10 UTC	Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $1.48	$0.00	Disclosure SEC source: 0001415889-21-002612 · form4-05202021_040528.xml · derivative · entry 1 Kariv Tomer · CIK 0001568077 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-19 F1 · derivative.exercise_date: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. F2 · ownership.direct: The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner. Read SEC document
May 13, 2021 Filed May 17, 2021 11:00 UTC	Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180	PurchaseCommon Stock	592,592	$1.35	$799,999.20	Disclosure SEC source: 0001104659-21-067333 · tm2116620d1_4s.xml · nonDerivative · entry 4 Kariv Tomer · CIK 0001568077 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pontifax Investment Fund Disclosed balance after: 616,592 F1 · kind: Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021. F1 · price: Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021. F5 · ownership.nature: Represents shares of the Issuer held by Pontifax Late Stage Fund L.P.("Late Stage Fund"). Pontifax Late Stage GP Ltd., the general partner of Late Stage Fund, has a Strategic Alliance Agreement with Pontifax IV. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by Late Stage Fund. Mr. Kariv disclaims beneficial ownership of such shares, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
May 13, 2021 Filed May 17, 2021 11:00 UTC	Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180	PurchaseCommon Stock	1,422,222	$1.35	$1,919,999.70	Disclosure SEC source: 0001104659-21-067333 · tm2116620d1_4s.xml · nonDerivative · entry 3 Kariv Tomer · CIK 0001568077 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pontifax Investment Fund Disclosed balance after: 1,989,551 F1 · kind: Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021. F1 · price: Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021. F4 · ownership.nature: Represents shares of the Issuer held by Pontifax (China) IV, L.P. ("China IV"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by China IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
May 13, 2021 Filed May 17, 2021 11:00 UTC	Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180	PurchaseCommon Stock	2,630,487	$1.35	$3,551,157.45	Disclosure SEC source: 0001104659-21-067333 · tm2116620d1_4s.xml · nonDerivative · entry 2 Kariv Tomer · CIK 0001568077 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pontifax Investment Fund Disclosed balance after: 3,679,797 F1 · kind: Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021. F1 · price: Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021. F3 · ownership.nature: Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
May 13, 2021 Filed May 17, 2021 11:00 UTC	Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180	PurchaseCommon Stock	1,280,624	$1.35	$1,728,842.40	Disclosure SEC source: 0001104659-21-067333 · tm2116620d1_4s.xml · nonDerivative · entry 1 Kariv Tomer · CIK 0001568077 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Pontifax Investment Fund Disclosed balance after: 1,791,470 F1 · kind: Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021. F1 · price: Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021. F2 · ownership.nature: Represents shares of the Issuer held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Pontifax IV GP L.P. ("Pontifax IV") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the general partner of Pontifax IV. Mr. Kariv is a Managing Partner of Management 4. By virtue of this relationship, Mr. Kariv may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Mr. Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
November 17, 2020 Filed Nov 19, 2020 16:39 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	PurchaseCommon Stock	6,000	$50.00	$300,000.00	Disclosure SEC source: 0001209191-20-059410 · doc4.xml · nonDerivative · entry 4 Kariv Tomer · CIK 0001568077 · Director · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 155,262 F4 · ownership.nature: The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, each of Management 4 and the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds. F5 · ownership.nature: Each of Management 4, Late Stage GP and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
November 17, 2020 Filed Nov 19, 2020 16:39 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	PurchaseCommon Stock	14,400	$50.00	$720,000.00	Disclosure SEC source: 0001209191-20-059410 · doc4.xml · nonDerivative · entry 3 Kariv Tomer · CIK 0001568077 · Director · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,228,326 F3 · ownership.nature: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
November 17, 2020 Filed Nov 19, 2020 16:39 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	PurchaseCommon Stock	12,966	$50.00	$648,300.00	Disclosure SEC source: 0001209191-20-059410 · doc4.xml · nonDerivative · entry 2 Kariv Tomer · CIK 0001568077 · Director · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,122,768 F2 · ownership.nature: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
November 17, 2020 Filed Nov 19, 2020 16:39 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	PurchaseCommon Stock	26,634	$50.00	$1,331,700.00	Disclosure SEC source: 0001209191-20-059410 · doc4.xml · nonDerivative · entry 1 Kariv Tomer · CIK 0001568077 · Director · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax Late Stage Fund L.P. · CIK 0001793769 · 10% owner Pontifax Late Stage GP Ltd. · CIK 0001793770 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,288,151 F1 · ownership.nature: The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
May 20, 2020 Filed May 22, 2020 20:10 UTC	Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $3.39	$0.00	Disclosure SEC source: 0001415889-20-001302 · form4-05222020_040521.xml · derivative · entry 1 Kariv Tomer · CIK 0001568077 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-20 F1 · derivative.exercise_date: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 20, 2021 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. F2 · ownership.direct: The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner. Read SEC document
April 13, 2020 Filed Apr 13, 2020 17:13 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	ConversionSeries C Preferred Stock · Derivative	36,858	$0.00	$0.00	Disclosure SEC source: 0001209191-20-024226 · doc4.xml · derivative · entry 26 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 36,858 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F5 · ownership.nature: The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, each of Management 4 and the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds. F6 · ownership.nature: Each of Management 4, Late Stage GP and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
April 13, 2020 Filed Apr 13, 2020 17:13 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	ConversionSeries C Preferred Stock · Derivative	79,653	$0.00	$0.00	Disclosure SEC source: 0001209191-20-024226 · doc4.xml · derivative · entry 25 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 79,653 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F4 · ownership.nature: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
April 13, 2020 Filed Apr 13, 2020 17:13 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	ConversionSeries C Preferred Stock · Derivative	88,460	$0.00	$0.00	Disclosure SEC source: 0001209191-20-024226 · doc4.xml · derivative · entry 24 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 88,460 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F3 · ownership.nature: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
April 13, 2020 Filed Apr 13, 2020 17:13 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	ConversionSeries C Preferred Stock · Derivative	163,612	$0.00	$0.00	Disclosure SEC source: 0001209191-20-024226 · doc4.xml · derivative · entry 23 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 163,612 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
April 13, 2020 Filed Apr 13, 2020 17:13 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	ConversionSeries B-1 Preferred Stock · Derivative	68,654	$0.00	$0.00	Disclosure SEC source: 0001209191-20-024226 · doc4.xml · derivative · entry 22 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 68,654 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F5 · ownership.nature: The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, each of Management 4 and the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds. F6 · ownership.nature: Each of Management 4, Late Stage GP and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
April 13, 2020 Filed Apr 13, 2020 17:13 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	ConversionSeries B-1 Preferred Stock · Derivative	91,538	$0.00	$0.00	Disclosure SEC source: 0001209191-20-024226 · doc4.xml · derivative · entry 21 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 91,538 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F4 · ownership.nature: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
April 13, 2020 Filed Apr 13, 2020 17:13 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	ConversionSeries B-1 Preferred Stock · Derivative	82,425	$0.00	$0.00	Disclosure SEC source: 0001209191-20-024226 · doc4.xml · derivative · entry 20 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 82,425 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F3 · ownership.nature: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
April 13, 2020 Filed Apr 13, 2020 17:13 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	ConversionSeries B-1 Preferred Stock · Derivative	169,307	$0.00	$0.00	Disclosure SEC source: 0001209191-20-024226 · doc4.xml · derivative · entry 19 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 169,307 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
April 13, 2020 Filed Apr 13, 2020 17:13 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	ConversionSeries A Preferred Stock · Derivative	737,226	$0.00	$0.00	Disclosure SEC source: 0001209191-20-024226 · doc4.xml · derivative · entry 18 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 737,226 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F4 · ownership.nature: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
April 13, 2020 Filed Apr 13, 2020 17:13 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	ConversionSeries A Preferred Stock · Derivative	663,825	$0.00	$0.00	Disclosure SEC source: 0001209191-20-024226 · doc4.xml · derivative · entry 17 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 663,825 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F3 · ownership.nature: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
April 13, 2020 Filed Apr 13, 2020 17:13 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	ConversionSeries A Preferred Stock · Derivative	1,363,542	$0.00	$0.00	Disclosure SEC source: 0001209191-20-024226 · doc4.xml · derivative · entry 16 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,363,542 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
April 13, 2020 Filed Apr 13, 2020 17:13 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	PurchaseCommon Stock	43,750	$16.00	$700,000.00	Disclosure SEC source: 0001209191-20-024226 · doc4.xml · nonDerivative · entry 15 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 149,262 F5 · ownership.nature: The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, each of Management 4 and the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds. F6 · ownership.nature: Each of Management 4, Late Stage GP and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
April 13, 2020 Filed Apr 13, 2020 17:13 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	PurchaseCommon Stock	105,000	$16.00	$1,680,000.00	Disclosure SEC source: 0001209191-20-024226 · doc4.xml · nonDerivative · entry 14 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,213,926 F4 · ownership.nature: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
April 13, 2020 Filed Apr 13, 2020 17:13 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	PurchaseCommon Stock	94,546	$16.00	$1,512,736.00	Disclosure SEC source: 0001209191-20-024226 · doc4.xml · nonDerivative · entry 13 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,109,802 F3 · ownership.nature: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
April 13, 2020 Filed Apr 13, 2020 17:13 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	PurchaseCommon Stock	194,203	$16.00	$3,107,248.00	Disclosure SEC source: 0001209191-20-024226 · doc4.xml · nonDerivative · entry 12 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,261,517 F2 · ownership.nature: The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
April 13, 2020 Filed Apr 13, 2020 17:13 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	ConversionCommon Stock	36,858	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-024226 · doc4.xml · nonDerivative · entry 11 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 105,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F5 · ownership.nature: The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, each of Management 4 and the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds. F6 · ownership.nature: Each of Management 4, Late Stage GP and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
April 13, 2020 Filed Apr 13, 2020 17:13 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	ConversionCommon Stock	79,653	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-024226 · doc4.xml · nonDerivative · entry 10 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,108,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F4 · ownership.nature: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
April 13, 2020 Filed Apr 13, 2020 17:13 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	ConversionCommon Stock	88,460	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-024226 · doc4.xml · nonDerivative · entry 9 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,015,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F3 · ownership.nature: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
April 13, 2020 Filed Apr 13, 2020 17:13 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	ConversionCommon Stock	163,612	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-024226 · doc4.xml · nonDerivative · entry 8 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,067,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
April 13, 2020 Filed Apr 13, 2020 17:13 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	ConversionCommon Stock	68,654	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-024226 · doc4.xml · nonDerivative · entry 7 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 68,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F5 · ownership.nature: The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, each of Management 4 and the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds. F6 · ownership.nature: Each of Management 4, Late Stage GP and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
April 13, 2020 Filed Apr 13, 2020 17:13 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	ConversionCommon Stock	91,538	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-024226 · doc4.xml · nonDerivative · entry 6 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,029,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F4 · ownership.nature: The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document
April 13, 2020 Filed Apr 13, 2020 17:13 UTC	Keros Therapeutics, Inc. KROS · Entity 6242	ConversionCommon Stock	82,425	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-024226 · doc4.xml · nonDerivative · entry 5 Kariv Tomer · CIK 0001568077 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 926,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F3 · ownership.nature: The securities are held by Pontifax (Cayman) IV, L.P. ("Cayman IV"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.